Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Ginecol Obstet Mex ; 79(7): 403-10, 2011 Jul.
Artigo em Espanhol | MEDLINE | ID: mdl-21966834

RESUMO

BACKGROUND: premature rupture of membranes occurs between 5 and 15% of pregnancies, of these, 10% occurs at term and preterm 2 to 3.5%. OBJECTIVE: To compare maternal and perinatal outcomes from the use of erythromycin or clindamycin in women with preterm premature rupture of membranes with conservative treatment at the Regional General Hospital No. 36. PATIENTS AND METHODS: comparative, prospective, randomized study conducted at the Regional General Hospital No. 36 of the Instituto Mexicano del Seguro Social, Puebla. The most common risk factors were cervical infections (55%) and urinary tract infection (55%). A history of premature rupture of membranes in pregnancy was reported in 12.5% of patients. Group A was prescribed erythromycin and group B, standard-dose clindamycin, these were the independent variables. Maternal outcomes (deciduoendometritis and chorioamnionitis) and perinatal (respiratory distress syndrome, necrotizing enterocolitis and sepsis) were the dependent variables. Fisher exact test was applied to the results of the study. RESULTS: about perinatal outcome, sepsis was expressed more frequently in the clindamycin group (60%) compared with erythromycin (35%). The occurrence of respiratory distress syndrome was similar in both groups, 70 and 75% respectively. For necrotizing enterocolitis, 25 and 5%. Maternal alterations as chorioamnionitis occurred in 20% of patients in group A and 5% in group B. Endometritis results were similar in both groups. CONCLUSIONS: comparing the maternal and perinatal outcomes with conservative management of premature rupture of membranes, results were better in the group treated with erythromycin. It is not possible to prove it statistically because of the sample size.


Assuntos
Antibacterianos/uso terapêutico , Antibioticoprofilaxia , Corioamnionite/prevenção & controle , Clindamicina/uso terapêutico , Endometrite/prevenção & controle , Enterocolite Necrosante/prevenção & controle , Eritromicina/uso terapêutico , Ruptura Prematura de Membranas Fetais/tratamento farmacológico , Doenças do Prematuro/prevenção & controle , Resultado da Gravidez , Sepse/prevenção & controle , Adulto , Corioamnionite/epidemiologia , Corioamnionite/etiologia , Endometrite/epidemiologia , Endometrite/etiologia , Enterocolite Necrosante/epidemiologia , Enterocolite Necrosante/etiologia , Feminino , Humanos , Recém-Nascido , Doenças do Prematuro/epidemiologia , Doenças do Prematuro/etiologia , Trabalho de Parto Prematuro , Gravidez , Complicações Infecciosas na Gravidez/tratamento farmacológico , Estudos Prospectivos , Síndrome do Desconforto Respiratório do Recém-Nascido/epidemiologia , Fatores de Risco , Sepse/epidemiologia , Sepse/etiologia , Infecções Urinárias/complicações , Infecções Urinárias/tratamento farmacológico , Cervicite Uterina/complicações , Cervicite Uterina/tratamento farmacológico , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...